within Pharmacolibrary.Drugs.ATC.L;

model L01XK06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.38,
    Cl             = 0.26166666666666666,
    adminDuration  = 600,
    adminMass      = 0.06,
    adminCount     = 1,
    Vd             = 0.091,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006266666666666667,
    Tlag           = 12.9
  );

  annotation(Documentation(
    info ="<html><body><p>Pamiparib is an orally bioavailable, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes PARP1 and PARP2. It is indicated for the treatment of certain types of ovarian, fallopian tube, or primary peritoneal cancer, especially in patients with germline BRCA mutations, and is approved in some countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated in adult cancer patients after oral administration.</p><h4>References</h4><ol><li>Yi Zeng, Oluwatobi Arisa, Cody J Peer, Antonio Fojo, William D Figg,PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.,Seminars in oncology,2024<a href='https://pubmed.ncbi.nlm.nih.gov/37880048/'>https://pubmed.ncbi.nlm.nih.gov/37880048/</a></li><li>Song Mu, Chester Lin, Anna Skrzypczyk-Ostaszewicz, Iurie Bulat, Marina Maglakelidze, Viera Skarbova, Claudia Andreu-Vieyra, Srikumar Sahasranaman,The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.,Cancer chemotherapy and pharmacology,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33772633/'>https://pubmed.ncbi.nlm.nih.gov/33772633/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XK06;
